Contact
searchSearch
HMP Global

Rheumatology Topic Center

Featured Article

News
No Increased Multiple Myeloma Risk Found With Biologic or Targeted DMARD Use in Veterans With Rheumatoid Arthritis
10/07/2025
Grace Taylor, MS, MA
A large Veterans Health Administration (VHA) study found no significant difference in multiple myeloma incidence between patients with rheumatoid arthritis treated with biologic or targeted synthetic disease-modifying anti-rheumatic drugs...
A large Veterans Health Administration (VHA) study found no significant difference in multiple myeloma incidence between patients with rheumatoid arthritis treated with biologic or targeted synthetic disease-modifying anti-rheumatic drugs...
A large Veterans Health...
10/07/2025
First Report Managed Care
News
Study Highlights Motivators and Barriers to Clinical Trial Enrollment in Rheumatoid Arthritis
05/07/2025
Grace Taylor, MS, MA
New findings reveal what motivates patients with rheumatoid arthritis to participate in clinical trials.
New findings reveal what motivates patients with rheumatoid arthritis to participate in clinical trials.
New findings reveal what...
05/07/2025
First Report Managed Care
News
Patients With Rheumatoid Arthritis Experience Substantial Economic and Quality-of-Life Burden
04/08/2025
Grace Taylor, MS, MA
Using national survey data, researchers found that rheumatoid arthritis imposes a substantial economic and humanistic burden, driven largely by prescription costs and impaired daily functioning.
Using national survey data, researchers found that rheumatoid arthritis imposes a substantial economic and humanistic burden, driven largely by prescription costs and impaired daily functioning.
Using national survey data,...
04/08/2025
First Report Managed Care
News
Adverse Events Common With Glucocorticoids for Polymyalgia Rheumatica
04/17/2024
Jolynn Tumolo
Although glucocorticoid treatment reduced inflammatory parameters in real-world patients with polymyalgia rheumatica (PMR), more than a third still showed above-normal levels throughout a 52-week follow-up period, according to study results...
Although glucocorticoid treatment reduced inflammatory parameters in real-world patients with polymyalgia rheumatica (PMR), more than a third still showed above-normal levels throughout a 52-week follow-up period, according to study results...
Although glucocorticoid...
04/17/2024
First Report Managed Care
News
Identifying Large-Vessel Vasculitis in Polymyalgia Rheumatica: Key Clinical and Laboratory Red Flags
04/05/2024
Lisa Kuhns, PhD, MD
Potential red flags for large-vessel vasculitis in isolated polymyalgia rheumatica (PMR) include inflammatory back pain, significant pelvic involvement, widespread lower extremity pain, marked inflammatory response indicated by specific lab...
Potential red flags for large-vessel vasculitis in isolated polymyalgia rheumatica (PMR) include inflammatory back pain, significant pelvic involvement, widespread lower extremity pain, marked inflammatory response indicated by specific lab...
Potential red flags for...
04/05/2024
First Report Managed Care
News
Potential for Target-To-Treat Strategies for Polymyalgia Rheumatica and Giant Cell Arthritis
03/28/2024

Emry Lloyd

Emry Lloyd
Different target-to-treat strategies for polymyalgia rheumatica and giant cell arthritis and how physicians can understand these strategies to suitably treat patients were revealed in a literature review.
Different target-to-treat strategies for polymyalgia rheumatica and giant cell arthritis and how physicians can understand these strategies to suitably treat patients were revealed in a literature review.
Different target-to-treat...
03/28/2024
First Report Managed Care
News
Task Force Publishes Target-To-Treat Guidance for GCA and PMR
03/12/2024
Jolynn Tumolo
An international task force recently published the first target-to-treat (T2T) recommendations for patients with giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) in the Annals of the Rheumatic Diseases.
An international task force recently published the first target-to-treat (T2T) recommendations for patients with giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) in the Annals of the Rheumatic Diseases.
An international task force...
03/12/2024
First Report Managed Care
News
Therapy Reduces Disease Activity in Patients With Polymyalgia Rheumatica
02/15/2023
Hannah Musick
A monoclonal antibody reduced disease activity in patients with polymyalgia rheumatica, but researchers say more evidence is needed to clarify the agent's potential benefits and harm.
A monoclonal antibody reduced disease activity in patients with polymyalgia rheumatica, but researchers say more evidence is needed to clarify the agent's potential benefits and harm.
A monoclonal antibody reduced...
02/15/2023
First Report Managed Care
News
Adalimumab vs Etanercept for Rheumatoid Arthritis: Comparing Adverse Reactions, Drug Survival
02/03/2023
Jolynn Tumolo
Researchers evaluated the frequency of adverse drug reactions, incidence of treatment discontinuation, and other drug-related outcomes in patients with rheumatoid arthritis treated with adalimumab or etanercept.
Researchers evaluated the frequency of adverse drug reactions, incidence of treatment discontinuation, and other drug-related outcomes in patients with rheumatoid arthritis treated with adalimumab or etanercept.
Researchers evaluated the...
02/03/2023
First Report Managed Care
News
Room for Improvement in Polymyalgia Rheumatica Referral, Management
01/26/2023
Jolynn Tumolo
“A large proportion of people with polymyalgia rheumatica are not referred for diagnosis," according to findings from a new survey.
“A large proportion of people with polymyalgia rheumatica are not referred for diagnosis," according to findings from a new survey.
“A large proportion of people...
01/26/2023
First Report Managed Care
News
Treatment Reduces Disease Activity in Patients With Steroid-Refractory Polymyalgia Rheumatica
01/20/2023
Maria Asimopoulos
For patients with relapsing polymalgia rheumatica, an anti-IL-6Rα monoclonal antibody demonstrated significant efficacy vs placebo, according to recent findings.
For patients with relapsing polymalgia rheumatica, an anti-IL-6Rα monoclonal antibody demonstrated significant efficacy vs placebo, according to recent findings.
For patients with relapsing...
01/20/2023
First Report Managed Care

Newsfeed

News
No Increased Multiple Myeloma Risk Found With Biologic or Targeted DMARD Use in Veterans With Rheumatoid Arthritis
10/07/2025
Grace Taylor, MS, MA
A large Veterans Health Administration (VHA) study found no significant difference in multiple myeloma incidence between patients with rheumatoid arthritis treated with biologic or targeted synthetic disease-modifying anti-rheumatic drugs...
A large Veterans Health Administration (VHA) study found no significant difference in multiple myeloma incidence between patients with rheumatoid arthritis treated with biologic or targeted synthetic disease-modifying anti-rheumatic drugs...
A large Veterans Health...
10/07/2025
First Report Managed Care
News
Study Highlights Motivators and Barriers to Clinical Trial Enrollment in Rheumatoid Arthritis
05/07/2025
Grace Taylor, MS, MA
New findings reveal what motivates patients with rheumatoid arthritis to participate in clinical trials.
New findings reveal what motivates patients with rheumatoid arthritis to participate in clinical trials.
New findings reveal what...
05/07/2025
First Report Managed Care
News
Patients With Rheumatoid Arthritis Experience Substantial Economic and Quality-of-Life Burden
04/08/2025
Grace Taylor, MS, MA
Using national survey data, researchers found that rheumatoid arthritis imposes a substantial economic and humanistic burden, driven largely by prescription costs and impaired daily functioning.
Using national survey data, researchers found that rheumatoid arthritis imposes a substantial economic and humanistic burden, driven largely by prescription costs and impaired daily functioning.
Using national survey data,...
04/08/2025
First Report Managed Care
News
Adverse Events Common With Glucocorticoids for Polymyalgia Rheumatica
04/17/2024
Jolynn Tumolo
Although glucocorticoid treatment reduced inflammatory parameters in real-world patients with polymyalgia rheumatica (PMR), more than a third still showed above-normal levels throughout a 52-week follow-up period, according to study results...
Although glucocorticoid treatment reduced inflammatory parameters in real-world patients with polymyalgia rheumatica (PMR), more than a third still showed above-normal levels throughout a 52-week follow-up period, according to study results...
Although glucocorticoid...
04/17/2024
First Report Managed Care
News
Identifying Large-Vessel Vasculitis in Polymyalgia Rheumatica: Key Clinical and Laboratory Red Flags
04/05/2024
Lisa Kuhns, PhD, MD
Potential red flags for large-vessel vasculitis in isolated polymyalgia rheumatica (PMR) include inflammatory back pain, significant pelvic involvement, widespread lower extremity pain, marked inflammatory response indicated by specific lab...
Potential red flags for large-vessel vasculitis in isolated polymyalgia rheumatica (PMR) include inflammatory back pain, significant pelvic involvement, widespread lower extremity pain, marked inflammatory response indicated by specific lab...
Potential red flags for...
04/05/2024
First Report Managed Care
News
Potential for Target-To-Treat Strategies for Polymyalgia Rheumatica and Giant Cell Arthritis
03/28/2024

Emry Lloyd

Emry Lloyd
Different target-to-treat strategies for polymyalgia rheumatica and giant cell arthritis and how physicians can understand these strategies to suitably treat patients were revealed in a literature review.
Different target-to-treat strategies for polymyalgia rheumatica and giant cell arthritis and how physicians can understand these strategies to suitably treat patients were revealed in a literature review.
Different target-to-treat...
03/28/2024
First Report Managed Care
News
Task Force Publishes Target-To-Treat Guidance for GCA and PMR
03/12/2024
Jolynn Tumolo
An international task force recently published the first target-to-treat (T2T) recommendations for patients with giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) in the Annals of the Rheumatic Diseases.
An international task force recently published the first target-to-treat (T2T) recommendations for patients with giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) in the Annals of the Rheumatic Diseases.
An international task force...
03/12/2024
First Report Managed Care
News
Therapy Reduces Disease Activity in Patients With Polymyalgia Rheumatica
02/15/2023
Hannah Musick
A monoclonal antibody reduced disease activity in patients with polymyalgia rheumatica, but researchers say more evidence is needed to clarify the agent's potential benefits and harm.
A monoclonal antibody reduced disease activity in patients with polymyalgia rheumatica, but researchers say more evidence is needed to clarify the agent's potential benefits and harm.
A monoclonal antibody reduced...
02/15/2023
First Report Managed Care
News
Adalimumab vs Etanercept for Rheumatoid Arthritis: Comparing Adverse Reactions, Drug Survival
02/03/2023
Jolynn Tumolo
Researchers evaluated the frequency of adverse drug reactions, incidence of treatment discontinuation, and other drug-related outcomes in patients with rheumatoid arthritis treated with adalimumab or etanercept.
Researchers evaluated the frequency of adverse drug reactions, incidence of treatment discontinuation, and other drug-related outcomes in patients with rheumatoid arthritis treated with adalimumab or etanercept.
Researchers evaluated the...
02/03/2023
First Report Managed Care
News
Room for Improvement in Polymyalgia Rheumatica Referral, Management
01/26/2023
Jolynn Tumolo
“A large proportion of people with polymyalgia rheumatica are not referred for diagnosis," according to findings from a new survey.
“A large proportion of people with polymyalgia rheumatica are not referred for diagnosis," according to findings from a new survey.
“A large proportion of people...
01/26/2023
First Report Managed Care
News
House Passes Bill to Extend ACA Premium Tax Credits
01/13/2026
Hannah Musick
The US House has advanced a bipartisan-backed bill to extend enhanced Affordable Care Act (ACA) premium tax credits, setting up a high-stakes Senate debate with major implications for insurance affordability and patient access to care.
The US House has advanced a bipartisan-backed bill to extend enhanced Affordable Care Act (ACA) premium tax credits, setting up a high-stakes Senate debate with major implications for insurance affordability and patient access to care.
The US House has advanced a...
01/13/2026
First Report Managed Care
News
Specialist Access Eliminates Racial Gaps in Rheumatoid Arthritis DMARD Use
01/12/2026
Lisa Kuhns, PhD, MD
Racial inequities in access to modern rheumatoid arthritis (RA) therapies persist across the United States, but disappear among patients who reach rheumatology care, according to study results published in The Journal of Rheumatology.
Racial inequities in access to modern rheumatoid arthritis (RA) therapies persist across the United States, but disappear among patients who reach rheumatology care, according to study results published in The Journal of Rheumatology.
Racial inequities in access to...
01/12/2026
First Report Managed Care
News
CMS Establishes Office of Rural Health Transformation Nationwide
01/09/2026
Grace Taylor, MS, MA
The Centers for Medicare & Medicaid Services (CMS) has formally launched the Office of Rural Health Transformation, creating a dedicated hub to oversee a $50 billion, 5-year effort to strengthen rural health systems and expand access to care...
The Centers for Medicare & Medicaid Services (CMS) has formally launched the Office of Rural Health Transformation, creating a dedicated hub to oversee a $50 billion, 5-year effort to strengthen rural health systems and expand access to care...
The Centers for Medicare &...
01/09/2026
First Report Managed Care
News
HHS Revises Childcare Payment Rules, Restoring Attendance-Based Billing
01/05/2026
Hannah Musick
HHS announced it will roll back childcare payment rules, restore attendance-based billing, and revise oversight requirements for federally funded programs.
HHS announced it will roll back childcare payment rules, restore attendance-based billing, and revise oversight requirements for federally funded programs.
HHS announced it will roll back...
01/05/2026
First Report Managed Care
News
AI Navigator Launched to Support Medicaid and SNAP Members Amid Policy Shifts
12/22/2025
Hannah Musick
Social health platform Pyx Health has launched an AI-driven navigator aimed at helping US Medicaid and Supplemental Nutrition Assistance Program (SNAP) beneficiaries comply with new policy requirements under the One Big Beautiful Bill Act...
Social health platform Pyx Health has launched an AI-driven navigator aimed at helping US Medicaid and Supplemental Nutrition Assistance Program (SNAP) beneficiaries comply with new policy requirements under the One Big Beautiful Bill Act...
Social health platform Pyx...
12/22/2025
First Report Managed Care
News
CMS Unveils LEAD Model to Succeed ACO REACH in 2027
12/19/2025
Grace Taylor, MS, MA
The Centers for Medicare & Medicaid Services (CMS) is set to replace the Accountable Care Organization (ACO) REACH model with its longest-ever accountable care demonstration, a 10-year Long-Term Enhanced ACO Design (LEAD) model aimed at...
The Centers for Medicare & Medicaid Services (CMS) is set to replace the Accountable Care Organization (ACO) REACH model with its longest-ever accountable care demonstration, a 10-year Long-Term Enhanced ACO Design (LEAD) model aimed at...
The Centers for Medicare &...
12/19/2025
First Report Managed Care
News
Rising Denials and Payer Audits Intensify Financial Strain on Hospitals in 2025
12/16/2025
Lisa Kuhns, PhD, MD
Hospitals are facing rising financial pressure as denial amounts and payer audits continue to climb in 2025, signaling an unsustainable trend for many health systems, according to a new report from billing compliance and revenue integrity...
Hospitals are facing rising financial pressure as denial amounts and payer audits continue to climb in 2025, signaling an unsustainable trend for many health systems, according to a new report from billing compliance and revenue integrity...
Hospitals are facing rising...
12/16/2025
First Report Managed Care
News
Racial and Ethnic Differences Shape NSCLC Treatment Decision-Making in the US
12/11/2025
Hannah Musick
A new US survey study reveals significant racial and ethnic differences in how patients with non–small cell lung cancer (NSCLC) and their oncologists prioritize treatment goals, cultural needs, and shared decision-making, underscoring the...
A new US survey study reveals significant racial and ethnic differences in how patients with non–small cell lung cancer (NSCLC) and their oncologists prioritize treatment goals, cultural needs, and shared decision-making, underscoring the...
A new US survey study reveals...
12/11/2025
First Report Managed Care
News
A New Era for Medicaid: CMS Unveils the Blueprint for Engagement, Integrity, and Sustainability
12/09/2025
Danielle Sposato
The Centers for Medicare & Medicaid Services (CMS) released new guidance detailing how states should implement major Medicaid reforms included in the Working Families Tax Cut (WFTC) legislation (Public Law 119-21). These reforms mark some of...
The Centers for Medicare & Medicaid Services (CMS) released new guidance detailing how states should implement major Medicaid reforms included in the Working Families Tax Cut (WFTC) legislation (Public Law 119-21). These reforms mark some of...
The Centers for Medicare &...
12/09/2025
First Report Managed Care
News
Immune Marker Profiles Distinguish cSCC From BCC in Tumor Microenvironment Study
12/04/2025
Grace Taylor, MS, MA
A comprehensive tumor microenvironment analysis uncovers key immune marker patterns that sharply distinguish cutaneous squamous cell carcinoma (cSCC) from basal cell carcinoma (BCC), pointing to new opportunities for clinical risk...
A comprehensive tumor microenvironment analysis uncovers key immune marker patterns that sharply distinguish cutaneous squamous cell carcinoma (cSCC) from basal cell carcinoma (BCC), pointing to new opportunities for clinical risk...
A comprehensive tumor...
12/04/2025
First Report Managed Care

Insights

Interview
Lower Costs, Improved Outcomes for Patients Achieving Early RA Remission
07/23/2019
Peter M ten Klooster, PhD, assistant professor at the University of Twente in Enschede in the Netherlands, discusses why achieving early remission for patients with rheumatoid arthritis is important to payers and how it can result in...
Peter M ten Klooster, PhD, assistant professor at the University of Twente in Enschede in the Netherlands, discusses why achieving early remission for patients with rheumatoid arthritis is important to payers and how it can result in...
Peter M ten Klooster, PhD,...
07/23/2019
First Report Managed Care
Interview
Impact of Artificial Intelligence on Patient Outcomes, Cost of Care in RA
06/20/2019
Beau Norgeot, MS, of Bakar Computational Health Sciences Institute at the University of California, explains how artificial intelligence (AI) impacts the cost of care for patients with complex diseases, including rheumatoid arthritis, and...
Beau Norgeot, MS, of Bakar Computational Health Sciences Institute at the University of California, explains how artificial intelligence (AI) impacts the cost of care for patients with complex diseases, including rheumatoid arthritis, and...
Beau Norgeot, MS, of Bakar...
06/20/2019
First Report Managed Care
Interview
High Out-of-Pocket Costs Increase Medication Nonadherence Among Patients With RA
06/06/2019
Julie Gould
Parvaneh Heidari, PhD student at Monash University, explains why it is recommended that health policy makers globally identify an appropriate out-of-pocket amount to ensure costs do not affect medication adherence among patients with...
Parvaneh Heidari, PhD student at Monash University, explains why it is recommended that health policy makers globally identify an appropriate out-of-pocket amount to ensure costs do not affect medication adherence among patients with...
Parvaneh Heidari, PhD student at...
06/06/2019
First Report Managed Care
Interview
Techniques Used to Lessen Opioid Use, Address Rheumatologic Pain
05/09/2019
Nirav N Shah, MD, attending anesthesiologist and interventional pain management specialist at Northshore University Health System, explains how neuromodulation can help lessen pain caused by rheumatologic conditions as well as reduce opioid...
Nirav N Shah, MD, attending anesthesiologist and interventional pain management specialist at Northshore University Health System, explains how neuromodulation can help lessen pain caused by rheumatologic conditions as well as reduce opioid...
Nirav N Shah, MD, attending...
05/09/2019
First Report Managed Care
Interview
Why Higher Levels of Physical Activity Are Important in Preventing Chronic Diseases
04/11/2019
Jeffrey Sparks, MD, rheumatologist and population scientist, discusses the importance of high levels of physical activity and explains why he suspects physical activity has beneficial effects on the immune system and also lowers systemic...
Jeffrey Sparks, MD, rheumatologist and population scientist, discusses the importance of high levels of physical activity and explains why he suspects physical activity has beneficial effects on the immune system and also lowers systemic...
Jeffrey Sparks, MD,...
04/11/2019
First Report Managed Care
Interview
Assessing the Safety of a Treatment With A Label Warning for Patients With RA, COPD
04/08/2019
Samy Suissa, PhD, professor of Epidemiology, Biostatistics and Medicine at McGill University in Montreal, discusses a label warning on a rheumatoid arthritis (RA) drug for patients with RA and COPD and he explains that the choice of biologic...
Samy Suissa, PhD, professor of Epidemiology, Biostatistics and Medicine at McGill University in Montreal, discusses a label warning on a rheumatoid arthritis (RA) drug for patients with RA and COPD and he explains that the choice of biologic...
Samy Suissa, PhD, professor of...
04/08/2019
First Report Managed Care
Interview
Exploring the Cost Benefits of Cloud-Enabled Testing for RA Diagnosis
03/14/2019
Kata Bognar, PhD, research economist at Precision Health Economics, discusses how rapid, cloud-enabled, onsite lab testing for RA diagnosis is valuable to payers and can potentially lower the number of visits per patient.
Kata Bognar, PhD, research economist at Precision Health Economics, discusses how rapid, cloud-enabled, onsite lab testing for RA diagnosis is valuable to payers and can potentially lower the number of visits per patient.
Kata Bognar, PhD, research...
03/14/2019
First Report Managed Care
Interview
Improving Access to Care, Outcomes Through Telemedicine for Patients With RA
03/06/2019
Wendy Marder, MD, associate professor and clinical service chief of the division of rheumatology at Michigan Medicine in Ann Arbor, Michigan, discusses telemedicine in a rheumatology setting and explains how telemedicine will impact...
Wendy Marder, MD, associate professor and clinical service chief of the division of rheumatology at Michigan Medicine in Ann Arbor, Michigan, discusses telemedicine in a rheumatology setting and explains how telemedicine will impact...
Wendy Marder, MD, associate...
03/06/2019
First Report Managed Care
Saad Ashraf, MD presents Pulmonary Fibrosis webinar
Videos
Redefining Pulmonary Fibrosis Care With Nerandomilast
12/10/2025
Saad Ashraf, MD
In the final chapter of our pulmonary fibrosis webinar series, Dr Saad Ashraf discussed FDA-approved nerandomilast and what its introduction means for clinicians, payers, and patients living with interstitial lung disease.
In the final chapter of our pulmonary fibrosis webinar series, Dr Saad Ashraf discussed FDA-approved nerandomilast and what its introduction means for clinicians, payers, and patients living with interstitial lung disease.
In the final chapter of our...
12/10/2025
First Report Managed Care
MANAGED CARE Q&A
SDOH Interventions and Managed Care Performance: A Roadmap for Health Plans
12/05/2025
Karen Iapoce, RNC, MSN, CPHQ, LSSBB
Karen Iapoce explains how integrating social determinants of health into managed care workflows can drive measurable improvements in outcomes and Stars performance.
Karen Iapoce explains how integrating social determinants of health into managed care workflows can drive measurable improvements in outcomes and Stars performance.
Karen Iapoce explains how...
12/05/2025
First Report Managed Care
Ashis Kumar Das, MD
Interview
How the IRA Is Reshaping Drug Evaluation Through Medicare-Focused Real-World Evidence
12/04/2025
Ashis Kumar Das, PhD, MD, MPH
Discover how the Inflation Reduction Act (IRA) is transforming drug value assessment as Ashis Das, MD, PhD, breaks down what the Centers for Medicare & Medicaid Services (CMS) expects from manufacturers in today’s Medicare landscape.
Discover how the Inflation Reduction Act (IRA) is transforming drug value assessment as Ashis Das, MD, PhD, breaks down what the Centers for Medicare & Medicaid Services (CMS) expects from manufacturers in today’s Medicare landscape.
Discover how the Inflation...
12/04/2025
First Report Managed Care
Brandes Headshot
Interview
Navigating Medicaid Turbulence: What Community Providers Need to Know
12/01/2025
Jeff Brandes
Jeff Brandes discusses the national impact of Medicaid cuts, the administrative challenges forcing eligible patients off coverage, and the mounting strain on safety-net clinics.
Jeff Brandes discusses the national impact of Medicaid cuts, the administrative challenges forcing eligible patients off coverage, and the mounting strain on safety-net clinics.
Jeff Brandes discusses the...
12/01/2025
First Report Managed Care
MANAGED CARE Q&A
Turning Data into Equity: How Advanced Analytics and SDOH Integration Are Redefining Value-Based Care
11/25/2025
Michael Hoxter
Michael Hoxter, Chief Technology Officer at Lightbeam Health Solutions, discusses how advanced analytics, artificial intelligence (AI), and social determinants of health data are transforming population health management, driving efficiency,...
Michael Hoxter, Chief Technology Officer at Lightbeam Health Solutions, discusses how advanced analytics, artificial intelligence (AI), and social determinants of health data are transforming population health management, driving efficiency,...
Michael Hoxter, Chief Technology...
11/25/2025
First Report Managed Care
MANAGED CARE Q&A
Right-Sizing Star Ratings: How Health Plans Can Adapt to a Changing Landscape
11/25/2025
Marge Ciancetta
Cotiviti’s Marge Ciancetta highlights how mid-sized Medicare Advantage plans leverage local insight, operational agility, and innovation to outperform larger national competitors.
Cotiviti’s Marge Ciancetta highlights how mid-sized Medicare Advantage plans leverage local insight, operational agility, and innovation to outperform larger national competitors.
Cotiviti’s Marge Ciancetta...
11/25/2025
First Report Managed Care
MANAGED CARE Q&A
The Potential of AI as a Clinical Co‑Pilot
11/24/2025
Gregory Whisman, MD, MBA
A guest expert explores how artificial intelligence is emerging as a clinical co-pilot by streamlining administrative burdens, enhancing patient targeting and engagement, and supporting predictive care strategies to improve quality, reduce...
A guest expert explores how artificial intelligence is emerging as a clinical co-pilot by streamlining administrative burdens, enhancing patient targeting and engagement, and supporting predictive care strategies to improve quality, reduce...
A guest expert explores how...
11/24/2025
First Report Managed Care
Videos
Obesity Drugs for Medicare: What the GLP-1 Pricing Agreement Means for Access
11/20/2025
Adam Colborn, JD
Adam Colborn, JD, associate vice president for congressional affairs at the Academy of Managed Care Pharmacy, discusses how the Trump administration’s “most favored nation” drug-pricing agreements test the limits of executive authority,...
Adam Colborn, JD, associate vice president for congressional affairs at the Academy of Managed Care Pharmacy, discusses how the Trump administration’s “most favored nation” drug-pricing agreements test the limits of executive authority,...
Adam Colborn, JD, associate vice...
11/20/2025
First Report Managed Care
Pipe
Pipeline Projections
Emerging Migraine Treatments Challenge a Mature Market
11/20/2025
Roy Moore
Roy Moore of Clarivate’s market access team discussed the evolving migraine treatment landscape, highlighting the maturation of the acute and prophylactic markets, the emergence of new therapies such as triptan-COX-2 combinations, gepants,...
Roy Moore of Clarivate’s market access team discussed the evolving migraine treatment landscape, highlighting the maturation of the acute and prophylactic markets, the emergence of new therapies such as triptan-COX-2 combinations, gepants,...
Roy Moore of Clarivate’s market...
11/20/2025
First Report Managed Care
Videos
From Innovation to Implementation: Rethinking Access in Idiopathic Pulmonary Fibrosis
11/07/2025
Elizabeth Volkmann, MD, MS; Carole Tremonti, RN, MBA
As new therapies for idiopathic pulmonary fibrosis (IPF) emerge, healthcare stakeholders must navigate the balance between innovation and evidence-based coverage decisions. This webinar brings together clinical, regulatory, and payer...
As new therapies for idiopathic pulmonary fibrosis (IPF) emerge, healthcare stakeholders must navigate the balance between innovation and evidence-based coverage decisions. This webinar brings together clinical, regulatory, and payer...
As new therapies for idiopathic...
11/07/2025
First Report Managed Care

Current Issue

Oct/Nov/Dec Volume 22, Issue 4, First Report Managed Care
Current Issue
Issue Archive

Recent Stories

News
No Increased Multiple Myeloma Risk Found With Biologic or Targeted DMARD Use in Veterans With Rheumatoid Arthritis
10/07/2025
Grace Taylor, MS, MA
A large Veterans Health Administration (VHA) study found no significant difference in multiple myeloma incidence between patients with rheumatoid arthritis treated with biologic or targeted synthetic disease-modifying anti-rheumatic drugs...
A large Veterans Health Administration (VHA) study found no significant difference in multiple myeloma incidence between patients with rheumatoid arthritis treated with biologic or targeted synthetic disease-modifying anti-rheumatic drugs...
A large Veterans Health...
10/07/2025
First Report Managed Care
News
Study Highlights Motivators and Barriers to Clinical Trial Enrollment in Rheumatoid Arthritis
05/07/2025
Grace Taylor, MS, MA
New findings reveal what motivates patients with rheumatoid arthritis to participate in clinical trials.
New findings reveal what motivates patients with rheumatoid arthritis to participate in clinical trials.
New findings reveal what...
05/07/2025
First Report Managed Care
News
Patients With Rheumatoid Arthritis Experience Substantial Economic and Quality-of-Life Burden
04/08/2025
Grace Taylor, MS, MA
Using national survey data, researchers found that rheumatoid arthritis imposes a substantial economic and humanistic burden, driven largely by prescription costs and impaired daily functioning.
Using national survey data, researchers found that rheumatoid arthritis imposes a substantial economic and humanistic burden, driven largely by prescription costs and impaired daily functioning.
Using national survey data,...
04/08/2025
First Report Managed Care
News
Adverse Events Common With Glucocorticoids for Polymyalgia Rheumatica
04/17/2024
Jolynn Tumolo
Although glucocorticoid treatment reduced inflammatory parameters in real-world patients with polymyalgia rheumatica (PMR), more than a third still showed above-normal levels throughout a 52-week follow-up period, according to study results...
Although glucocorticoid treatment reduced inflammatory parameters in real-world patients with polymyalgia rheumatica (PMR), more than a third still showed above-normal levels throughout a 52-week follow-up period, according to study results...
Although glucocorticoid...
04/17/2024
First Report Managed Care
News
Identifying Large-Vessel Vasculitis in Polymyalgia Rheumatica: Key Clinical and Laboratory Red Flags
04/05/2024
Lisa Kuhns, PhD, MD
Potential red flags for large-vessel vasculitis in isolated polymyalgia rheumatica (PMR) include inflammatory back pain, significant pelvic involvement, widespread lower extremity pain, marked inflammatory response indicated by specific lab...
Potential red flags for large-vessel vasculitis in isolated polymyalgia rheumatica (PMR) include inflammatory back pain, significant pelvic involvement, widespread lower extremity pain, marked inflammatory response indicated by specific lab...
Potential red flags for...
04/05/2024
First Report Managed Care

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use